Humira use in pJIA extended

The licence for Humira (adalimumab) in polyarticular juvenile idiopathic arthritis (pJIA) has been extended to include the treatment of children from 4 years-old. Humira can be given in combination with methotrexate when the response to one or more DMARDs is inadequate, or as monotherapy if methotrexate is inappropriate or not tolerated.

The recommended dose is 24mg/m2 (max 40mg) by subcutaneous injection every other week. To enable accurate dosing, Humira solution for injection is now available as a vial, in addition to the prefilled pen and syringe presentations.

View Humira drug record

Further Information: Abbott Laboratories Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Humira now licensed for psoriasis treatment in children

Humira now licensed for psoriasis treatment in children

Humira (adalimumab) is now licensed for the treatment...

Humira licensed for paediatric Crohn's

Humira licensed for paediatric Crohn's

The licensed indications for Humira (adalimumab) have...

Humira approved for use in moderate Crohn's disease

Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have...

Humira: new treatment option for ulcerative colitis

Humira: new treatment option for ulcerative colitis

Humira (adalimumab) can now be prescribed for the treatment...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more